Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;57(6):1034-1037.
doi: 10.1038/s41409-022-01679-6. Epub 2022 Apr 16.

Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies

Lukas Kevlicius  1   2 , Ruta Cepulyte  3 , Dominika Vasilevska  4 , Laimonas Griskevicius  3   4 , Andrius Zucenka  3   4
Affiliations

Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies

Lukas Kevlicius et al. Bone Marrow Transplant. 2022 Jun.
No abstract available

PubMed Disclaimer

References

    1. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791–803. - DOI
    1. Zucenka A, Vaitekenaite V, Maneikis K, Davainis L, Pileckyte R, Trociukas I, et al. Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2021;56:2804–12. - DOI
    1. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2020;106:894–8. - DOI
    1. Zucenka A, Pileckyte R, Trociukas I, Peceliunas V, Vaitekenaite V, Maneikis K, et al. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies. Eur J Haematol. 2021;106:105–13. - DOI
    1. Zhang H, Nakauchi Y, Köhnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826–39. - DOI

MeSH terms

LinkOut - more resources